Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma

Cancer Letters

Volumn 249, Issue 2, 2007, Pages 188-197

  Sun, Baocun ^a   Zhang, Danfang ^a   Zhang, Shiwu ^a   Zhang, Wenzhi ^b   Guo, Hua ^a   Zhao, Xiulan ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN HUANHU HOSPITAL   (China)

Author keywords

Hypoxia induced factor 1 ; Matrix metalloproteinase; Melanoma; Mouse ischemic hindlimb model; Vasculogenic mimicry

Indexed keywords

FORMALDEHYDE; GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PARAFFIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER SIZE; CONTROLLED STUDY; FEMALE; HYPOXIA; IMMUNOHISTOCHEMISTRY; INOCULATION; LIMB ISCHEMIA; MALE; MELANOMA; MELANOMA CELL; METASTASIS; MICROENVIRONMENT; MOLECULAR MIMICRY; MOUSE; NONHUMAN; PERFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANOXIA; FEMALE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MUSCLE NEOPLASMS; NEOPLASM INVASIVENESS; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33947378293     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.08.016     Document Type: Article

References (49)

1. Aloia T.A., and Gershenwald J.E. Management of early-stage cutaneous melanoma. Curr. Probl. Surg. 42 (2005) 460-534
2. Pilati P., Mocellin S., Miotto D., Fitta C., Casara D., Ori C., Scalerta R., Nitti D., Lise M., and Rossi C.R. Hypoxic antiblastic stop-flow limb perfusion: clinical outcome and pharmacokinetic findings of a novel treatment for in transit melanoma metastases. Oncol. Rep. 12 (2004) 895-901
3. Guadagni S., Santinami M., Patuzzo R., Pilati P.L., Miotto D., Deraco M., Rossi C.R., Fiorentini G., Di Filippo F., Valenti M., and Amicucci G. Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study. Melanoma Res. 13 (2003) 51-58
4. Vaupel P., and Harrison L. Related. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 9 Suppl 5 (2004) 4-9
5. Rofstad E.K., Mathiesen B., and Galappathi K. Increased metastatic dissemination in human melanoma xenografts after subcurative radiation treatment: radiation-induced increase in fraction of hypoxic cells and hypoxia-induced up-regulation of urokinase-type plasminogen activator receptor. Cancer Res. 64 (2004) 13-18
6. Giatromanolaki A., Koukourakis M.I., Sowter H.M., Sivridis E., Gibson S., Gatter K.C., and Harris A.L. BNIP3 expression is linked with hypoxia-regulated protein expression and with poor prognosis in non-small cell lung cancer. Clin. Cancer Res. 10 (2004) 5566-5571
7. Maniotis A.J., Folberg R., Hess A., Seftor E.A., Gardner L.M., Pe'er J., Trent J.M., Meltzer P.S., and Hendrix M.J. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155 (1999) 739-752
8. Bissell M.J. Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name?. Am. J. Pathol. 155 (1999) 675-679
9. Sood A.K., Seftor E.A., Fletcher M.S., Gardner L.M., Heidger P.M., Buller R.E., Seftor R.E., and Hendrix M.J. Molecular determinants of ovarian cancer plasticity. Am. J. Pathol. 158 (2001) 1279-1288
10. Folberg R., Hendrix M.J., and Maniotis A.J. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. 156 (2000) 361-381
11. Seftor E.A., Meltzer P.S., Kirschmann D.A., Pe'er J., Maniotis A.J., Trent J.M., Folberg R., and Hendrix M.J. Molecular determinants of human uveal melanoma invasion and metastasis. Clin. Exp. Metastasis 19 (2002) 233-346
12. Hendrix M.J., Seftor R.E., Seftor E.A., Gruman L.M., Lee L.M., Nickoloff B.J., Miele L., Sheriff D.D., and Schatteman G.C. Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination. Cancer Res. 62 (2002) 665-668
13. Zhang R.P., Zhang W.H., Xue D.B., and Wei Y.W. Morphology of portal hypertension at the early stage of liver damage induced by CCl4: an experimental study with dogs. Zhonghua Yi Xue Za Zhi 84 (2004) 1118-1121
14. Dauda M.M., and Shehu S.M. Malignant melanoma: a review. Niger. Postgrad. Med. J. 12 (2005) 125-130
15. Scala S., Ottaiano A., Ascierto P.A., Cavalli M., Simeone E., Giuliano P., Napolitano M., Franco R., Botti G., and Castello G. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin. Cancer Res. 11 (2005) 1835-1841
16. Miotto D., Miotto D., Bertolo S., Minante M., Darisi T., Mocellin S., Casara D., Ori C., Foletto M., Rossi C.R., Lise M., and Nitti D. Hypoxic antiblastic stop-flow perfusion: clinical outcome and pharmacokinetic findings. J. Chemother. 16 Suppl 5 (2004) 444-447
17. Rossi C.R., Foletto M., Mocellin S., Pilati P., and Lise M. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann. Surg. Oncol. 11 (2004) 173-177
18. Grunhagen D.J., Brunstein F., Graveland W.J., van Geel A.N., de Wilt J.H., and Eggermont A.M. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transitmetastases. Ann. Surg. 240 (2004) 939-947
19. Guadagni S., Russo F., Rossi C.R., Pilati P.L., Miotto D., Fiorentini G., Deraco M., Santinami M., Palumbo G., Valenti M., and Amicucci G. Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma. Am. J. Surg. 183 (2002) 28-36
20. Laurenzi L., Natoli S., Di Filippo F., Calamaro A., Centulio F., Anza M., Cavaliere F., Marcelli M.E., Garinei R., and Arcuri E. Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha. J. Exp. Clin. Cancer Res. 23 (2004) 225-231
21. Gross J., Fuchs J., Machulik A., Jahnke V., Kietzmann T., and Bockmuhl U. Apoptosis, necrosis and hypoxia inducible factor-1 in human head and neck squamous cell carcinoma cultures. Int. J. Oncol. 27 (2005) 807-814
22. Weinmann M., Jendrossek V., Guner D., Goecke B., and Belka C. Cyclic exposure to hypoxia and reoxygenation selects for tumor cells with defects in mitochondrial apoptotic pathways. FASEB J. 18 (2004) 1906-1908
23. Seta K.A., and Millhorn D.E. Functional genomics approach to hypoxia signaling. J. Appl. Physiol. 96 (2004) 765-773
24. Kumar G.K., and Klein J.B. Analysis of expression and posttranslational modification of proteins during hypoxia. J. Appl. Physiol. 96 (2004) 1178-1186
25. Sood A.K., Fletcher M.S., and Hendrix M.J. The embryonic-like properties of aggressive human tumor cells. J. Soc. Gynecol. Investig. 9 (2002) 2-9
26. Seftor E.A., Meltzer P.S., Schatteman G.C., Gruman L.M., Hess A.R., Kirschmann D.A., Seftor R.E., and Hendrix M.J. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. Crit. Rev. Oncol. Hematol. 44 (2002) 17-27
27. Hao X., Sun B., Zhang S., and Zhao X. Microarray study of vasculogenic mimicry in bi-directional differentiation malignant tumor. Zhonghua Yi Xue Za Zhi 82 (2002) 1298-1302
28. Maniotis A.J., et al. Control of melanoma morphogenesis, endothelial survival, and perfusion by extracellular matrix. Lab. Invest. 82 (2002) 1031-1043
29. Folberg R., and Maniotis A.J. Vasculogenic mimicry. APMIS 112 (2004) 508-525
30. Lee Y.J., Nagai N., Siar C.H., Nakano K., Nagatsuka H., Tsujigiwa H., Roan C.H., and Gunduz M. Angioarchitecture of primary oral malignant melanomas. J. Histochem. Cytochem. 50 (2002) 1555-1562
31. Sun B.C., Zhang S.W., Zhao X.L., and Hao X.S. Study on vasculogenic mimicry in malignant melanoma. Zhonghua Bing Li Xue Za Zhi 32 (2003) 539-543
32. Maxwell P.H., Dachs G.U., Gleadle J.M., Nicholls L.G., Harris A.L., Stratford I.J., Hankinson O., Pugh C.W., and Ratcliffe P.J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 94 (1997) 8104-8109
33. Semenza G.L. Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem. Pharmacol. 59 (2000) 47-53
34. Vordermark D., and Brown J.M. Evaluation of hypoxia-inducible factor-1alpha (HIF-1alpha) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma: in vitro and xenograft studies. Int. J. Radiat. Oncol. Biol. Phys. 56 (2003) 1184-1193
35. Shams I., Avivi A., and Nevo E. Hypoxic stress tolerance of the blind subterranean mole rat: expression of erythropoietin and hypoxia-inducible factor 1 alpha. Proc. Natl. Acad. Sci. USA 101 (2004) 9698-9703
36. Olenyuk B.Z., Zhang G.J., Klco J.M., Nickols N.G., Kaelin Jr. W.G., and Dervan P.B. Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc. Natl. Acad. Sci. USA 01 (2004) 16768-16773
37. Jung F., Palmer L.A., Zhou N., and Johns R.A. Hypoxic regulation of inducible nitric oxide synthase via hypoxia inducible factor-1 in cardiac myocytes. Circ. Res. 86 (2000) 319-325
38. Biju M.P., Akai Y., Shrimanker N., and Haase V.H. Protection of HIF-1 deficient primary renal tubular epithelial cells from hypoxia induced cell death is glucose dependent. Am. J. Physiol. Renal. Physiol. 289 (2005) F1217-F1226
39. Lee J.W., Bae S.H., Jeong J.W., Kim S.H., and Kim K.W. Hypoxia-inducible factor (HIF-1) alpha: its protein stability and biological functions. Exp. Mol. Med. 36 (2004) 1-12
40. Pantuck A.J., Zeng G., Belldegrun A.S., and Figlin R.A. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin. Cancer Res. 9 (2003) 4641-4652
41. Kim S.J., Rabbani Z.N., Dewhirst M.W., Vujaskovic Z., Vollmer R.T., Schreiber E.G., Oosterwijk E., and Kelley M.J. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 49 (2005) 325-335
42. Hess A.R., Seftor E.A., Seftor R.E., and Hendrix M.J. Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res. 63 (2003) 4757-6472
43. Brat D.J., Castellano-Sanchez A.A., Hunter S.B., Pecot M., Cohen C., Hammond E.H., Devi S.N., Kaur B., and Van Meir E.G. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res. 64 (2004) 920-927
44. Drummond A.H., Beckett P., Brown P.D., Bone E.A., Davidson A.H., Galloway W.A., Gearing A.J., Huxley P., Laber D., McCourt M., Whittaker M., Wood L.M., and Wright A. Preclinical and clinical studies of MMP inhibitors in cancer. Ann. N Y Acad. Sci. 878 (1999) 228-235
45. Miyamori H., Takino T., Kobayashi Y., Tokai H., Itoh Y., Seiki M., and Sato H. Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane-type matrix metalloproteinases. J. Biol. Chem. 276 (2001) 28204-28211
46. Williams T.M., Medina F., Badano I., Hazan R.B., Hutchinson J., Muller W.J., Chopra N.G., Scherer P.E., Pestell R.G., and Lisanti M.P. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J. Biol. Chem. 279 (2004) 51630-51646
47. Gao N., Ding M., Zheng J.Z., Zhang Z., Leonard S.S., Liu K.J., Shi X., and Jiang B.H. Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J. Biol. Chem. 277 (2002) 31963-31971
48. Buchler P., Reber H.A., Buchler M., Shrinkante S., Buchler M.W., Friess H., Semenza G.L., and Hines O.J. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas 26 (2003) 56-64
49. Mizukami Y., Li J., Zhang X., Zimmer M.A., Iliopoulos O., and Chung D.C. Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res. 64 (2004) 1765-1772